Imagion Biosystems Limited is pleased to announce that it has received its 2020 R&D tax incentive claim of $2,612,159 from the Australian Taxation Office.
This is higher than the $2,197,028 received in respect of the 2019 claim and reflects increased R&D spend in 2020 as the Company undertook preparatory activities towards the first-in-human trial of its MagSense® imaging technology in HER2 positive breast cancer patients.
See the announcement.
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance